Merck Net Change in Short-term Investments 2012-2026 | MRK
Merck annual/quarterly net change in short-term investments history and growth rate from 2012 to 2026. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
- Merck net change in short-term investments for the quarter ending March 31, 2026 was $425M, a 38.89% increase year-over-year.
- Merck net change in short-term investments for the twelve months ending March 31, 2026 was $-6M, a 100.4% decline year-over-year.
- Merck annual net change in short-term investments for 2024 was $-0.142B, a 120.2% decline from 2023.
- Merck annual net change in short-term investments for 2023 was $0.703B, a 245.55% decline from 2022.
- Merck annual net change in short-term investments for 2022 was $-0.483B, a 147.12% decline from 2021.
|
Merck Annual Net Change in Short-term Investments (Millions of US $) |
|
|---|---|
| 2024 | $-142 |
| 2023 | $703 |
| 2022 | $-483 |
| 2021 | $1,025 |
| 2020 | $2,717 |
| 2019 | $5,420 |
| 2018 | $7,258 |
| 2017 | $4,925 |
| 2016 | $-1,298 |
| 2015 | $3,732 |
| 2014 | $-9,830 |
| 2013 | $-1,693 |
| 2012 | $-5,058 |
| 2011 | $-1,176 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |